Skip to main content
Profiles and Predictors of Neurodevelopmental Outcome at 5-6 Years in Children With a History of Acute Provoked Neonatal Seizures.
Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis.
Mutations in the Key Autophagy Tethering Factor EPG5 Link Neurodevelopmental and Neurodegenerative Disorders Including Early-Onset Parkinsonism.
High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis.
MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls.
Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
The gut microbiome in human neurological disease: A review.
Precision medicine in chronic disease management: The multiple sclerosis BioScreen.
Spinal cord gray matter atrophy correlates with multiple sclerosis disability.